FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W126098488> ?p ?o ?g. }

• W126098488 abstract "Abstract Introduction SGI-110 is a dinucleotide of decitabine and deoxyguanosine and is a potent inhibitor of DNA methylation in-vitro and in-vivo. A Phase 1 study established the biologically effective dose of SGI-110 in MDS/AML patients as 60 mg/m2 SQ daily x 5 and demonstrated clinical responses that correlated with hypomethylation induction. Here, we analyze AML patients treated at pharmacologically effective doses of SGI-110 to explore determinants of hypomethylation and response. Methods We studied patients with relapsed/refractory AML treated at therapeutic dose ranges of SGI-110 (36 mg/m2-125 mg/m2). DNA methylation pre/post treatment (for pharmacodynamics [PD]) was measured by bisulfite-pyrosequencing for the LINE-1 repetitive element and the INS6 CpG island gene promoter which is highly methylated in all somatic tissues. Gene expression at baseline and after treatment was measured by qPCR. Results We analyzed samples from 27 patients with AML. Median age was 64, (range, 29–86), 18 were Males (67%), 13 (48%) had poor risk cytogenetics at study entry and 59% had prior exposure to a hypomethylating agent. Overall, peak LINE-1 demethylation generally occurred on Day 8 and correlated strongly with INSL6 demethylation (R=0.95, p<0.001). In individual patients, peak LINE-1 demethylation ranged from +1% to -39%. We next examined baseline expression of a panel of genes (CDA, P15, P21, DNMT3B, DNMT3A, DNMT1, CTCF) as possible predictors of SGI-110 response. High expression of DNMT3b (but not DNMT1) was associated with a trend for reduced demethylation (R=-0.20, p>0.05). Unsupervised classification grouped the patients into four clusters: A (N=2), B (N=6), C (N=10), and D (N=9). Cluster D is characterized by high DNMT3b expression, low P15 expression, low CDA expression and reduced demethylation (demethylation average -10.9% in cluster D compared to -22.7% in clusters B and C, p=0.06). Next, we examined SGI-110 mediated induction of gene expression for the P15, P21, DNMT3B and CTCF genes. P15 was significantly induced in patients who were treated on the daily x 5 regimen (p=0.03) but not in patients receiving the weekly x 3 regimen. In this group of 14 patients with induced P15, P15 induction peaked on Day 8 and averaged a 2.4-fold increase. P15 induction was associated with a trend for increased demethylation on Day 8 (R=0.28) and on Day 29 (R=0.37), p>0.05 for both. Of the 27 patients, 5 showed major clinical responses (2 CR, 3 CRi/CRp). LINE-1 and INSL6 demethylation averaged -21.1% and -16.4% in responders compared to -13.1% and -11.3% in non-responders. A three gene classifier score (low CDA, low P15 and high DNMT3B) was associated with low LINE-1 demethylation (R=0.43, p=0.025) as well as resistance to SGI-110 (mean score 6.2 in non-responders compared to 0.5 in responders, p=0.047). Finally, peak induction of P15 was similar in responders and non-responders, but sustained induction (at Day 29) was higher in responders (3.1 fold) than in non-responders (1.0 fold). While a genetic signature of response could not be identified among those 8 genes that were examined by exome sequencing, mutations in IDH1 or IDH2 were identified in 5 patients. One of these patients was positive for substitution R132H of IDH1 (described to induce epigenetic alterations and may predict poor clinical outcome in AML) and achieved a CR in response to SGI-110 treatment. The TP53 polymorphism NM_000546:c.C215G:p.P72R, (associated with differential response to chemotherapy in AML), was identified in 9 subjects, 3 of whom responded to SGI-110. Conclusions At therapeutic doses of SGI-110, we identified a gene expression signature (high DNMT3B, low P15, and low CDA) that differentiates responders from non-responders to SGI-110 and we find trends for associations between demethylation and response, as well as sustained P15 induction and response. These associations will be further investigated in the ongoing Phase 2 study of SGI-110 in AML. Disclosures: Chung: Astex Pharmaceuticals Inc.: Research Funding. Off Label Use: SGI-110. Taverna:Astex Pharmaceuticals Inc.: Employment. Lyons:Astex Pharmaceuticals Inc.: Employment. Hao:Astex Pharmaceuticals Inc.: Employment. Azab:Astex Pharmaceuticals Inc.: Employment. Kantarjian:Astex Pharmaceuticals Inc.: Research Funding. Kropf:Astex Pharmaceuticals Inc.: Research Funding. Issa:Astex Pharmaceuticals Inc.: Honoraria, Research Funding." @default.
• W126098488 created "2016-06-24" @default.
• W126098488 creator A5018689852 @default.
• W126098488 creator A5019816977 @default.
• W126098488 creator A5033584583 @default.
• W126098488 creator A5050224107 @default.
• W126098488 creator A5062330946 @default.
• W126098488 creator A5064201088 @default.
• W126098488 creator A5079853830 @default.
• W126098488 creator A5090435894 @default.
• W126098488 date "2013-11-15" @default.
• W126098488 modified "2023-09-27" @default.
• W126098488 title "Determinants Of Demethylation and Clinical Response In AML Patients Treated With SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA) In a Phase 1 Study" @default.
• W126098488 doi "https://doi.org/10.1182/blood.v122.21.1442.1442" @default.
• W126098488 hasPublicationYear "2013" @default.
• W126098488 type Work @default.
• W126098488 sameAs 126098488 @default.
• W126098488 citedByCount "2" @default.
• W126098488 countsByYear W1260984882016 @default.
• W126098488 countsByYear W1260984882017 @default.
• W126098488 crossrefType "journal-article" @default.
• W126098488 hasAuthorship W126098488A5018689852 @default.
• W126098488 hasAuthorship W126098488A5019816977 @default.
• W126098488 hasAuthorship W126098488A5033584583 @default.
• W126098488 hasAuthorship W126098488A5050224107 @default.
• W126098488 hasAuthorship W126098488A5062330946 @default.
• W126098488 hasAuthorship W126098488A5064201088 @default.
• W126098488 hasAuthorship W126098488A5079853830 @default.
• W126098488 hasAuthorship W126098488A5090435894 @default.
• W126098488 hasConcept C104317684 @default.
• W126098488 hasConcept C111113717 @default.
• W126098488 hasConcept C112705442 @default.
• W126098488 hasConcept C126322002 @default.
• W126098488 hasConcept C140173407 @default.
• W126098488 hasConcept C150194340 @default.
• W126098488 hasConcept C16824249 @default.
• W126098488 hasConcept C190727270 @default.
• W126098488 hasConcept C202199734 @default.
• W126098488 hasConcept C2776012956 @default.
• W126098488 hasConcept C2776239401 @default.
• W126098488 hasConcept C2780235182 @default.
• W126098488 hasConcept C33288867 @default.
• W126098488 hasConcept C54355233 @default.
• W126098488 hasConcept C552990157 @default.
• W126098488 hasConcept C71924100 @default.
• W126098488 hasConcept C86803240 @default.
• W126098488 hasConcept C98274493 @default.
• W126098488 hasConceptScore W126098488C104317684 @default.
• W126098488 hasConceptScore W126098488C111113717 @default.
• W126098488 hasConceptScore W126098488C112705442 @default.
• W126098488 hasConceptScore W126098488C126322002 @default.
• W126098488 hasConceptScore W126098488C140173407 @default.
• W126098488 hasConceptScore W126098488C150194340 @default.
• W126098488 hasConceptScore W126098488C16824249 @default.
• W126098488 hasConceptScore W126098488C190727270 @default.
• W126098488 hasConceptScore W126098488C202199734 @default.
• W126098488 hasConceptScore W126098488C2776012956 @default.
• W126098488 hasConceptScore W126098488C2776239401 @default.
• W126098488 hasConceptScore W126098488C2780235182 @default.
• W126098488 hasConceptScore W126098488C33288867 @default.
• W126098488 hasConceptScore W126098488C54355233 @default.
• W126098488 hasConceptScore W126098488C552990157 @default.
• W126098488 hasConceptScore W126098488C71924100 @default.
• W126098488 hasConceptScore W126098488C86803240 @default.
• W126098488 hasConceptScore W126098488C98274493 @default.
• W126098488 hasLocation W1260984881 @default.
• W126098488 hasOpenAccess W126098488 @default.
• W126098488 hasPrimaryLocation W1260984881 @default.
• W126098488 hasRelatedWork W2441913745 @default.
• W126098488 hasRelatedWork W2504451653 @default.
• W126098488 hasRelatedWork W2529888484 @default.
• W126098488 hasRelatedWork W2532183409 @default.
• W126098488 hasRelatedWork W2545113688 @default.
• W126098488 hasRelatedWork W2550705242 @default.
• W126098488 hasRelatedWork W2555832724 @default.
• W126098488 hasRelatedWork W2556574691 @default.
• W126098488 hasRelatedWork W2559744569 @default.
• W126098488 hasRelatedWork W2561567034 @default.
• W126098488 hasRelatedWork W2579153536 @default.
• W126098488 hasRelatedWork W2582870314 @default.
• W126098488 hasRelatedWork W2588574125 @default.
• W126098488 hasRelatedWork W2589092980 @default.
• W126098488 hasRelatedWork W2593543199 @default.
• W126098488 hasRelatedWork W2599450528 @default.
• W126098488 hasRelatedWork W2780521890 @default.
• W126098488 hasRelatedWork W2963483321 @default.
• W126098488 hasRelatedWork W3046101848 @default.
• W126098488 hasRelatedWork W3136777595 @default.
• W126098488 isParatext "false" @default.
• W126098488 isRetracted "false" @default.
• W126098488 magId "126098488" @default.
• W126098488 workType "article" @default.